Patents by Inventor Daniel M. Solomon
Daniel M. Solomon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110262368Abstract: The present invention provides compounds of Formula (VII) and 11-keto analogs thereof, and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers of said compounds and said 11-keto analogs, having the general structure formula (VII): wherein L, R1, R2, R3, R4, and R5 are selected independently of each other and as defined herein. Also provided are pharmaceutical compositions, methods of preparing, and methods of using such compounds in the treatment and prophylaxis of a wide range of immune, autoimmune, and inflammatory diseases and conditions. The novel compounds of the present invention possess useful pharmacological activity while having unexpectedly low systemic activity. Thus, the compounds of the invention represent a safer alternative to those known glucocorticoids which have poor side-effect profiles.Type: ApplicationFiled: December 18, 2008Publication date: October 27, 2011Applicant: Schering CorporationInventors: John C. Anthes, Kevin D. McCormick, John A. Hey, Robert G. Aslanian, Purakkattle J. Biju, Michael Y. Berlin, Daniel M. Solomon, Philippa H. Solomon, Hongwu Yang, Yeon-Hee Lim, Yoon Joo Lee, Rema Danielle Bitar
-
Publication number: 20110182828Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having the general structure: wherein L, R1, R2, R3, R4, R5, and R6 are selected independently of each other and as defined herein. The present invention also provides compounds (and salts, solvates, esters, prodrugs, tautomers, and isomers) of Formulas II, III, IV, V, and VI, as defined herein. Also provided are pharmaceutical compositions, methods of preparing, and methods of using such compounds in the treatment and prophylaxis of a wide range of immune, autoimmune, and inflammatory diseases and conditions.Type: ApplicationFiled: December 18, 2008Publication date: July 28, 2011Applicant: Schering CorporationInventors: John C. Anthes, Kevin D. Mccormick, John A. Hey, Robert G. Aslanian, Purakkattle J. Biju, Michael Y. Berlin, Daniel M. Solomon, Phillippa H. Solomon, Hongwu Yang, Yeon-Hee Lim, Yoon Joo Lee, Rema Danielle Bitar
-
Patent number: 7879880Abstract: Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein M1 is M2 is N; X is a bond, optionally substituted alkylene, alkenylene, —O—, —CH2N(R12)—, —N(R12)CH2—, —N(R12)—, —NHC(O)—, —OCH2—, —CH2O—, or —S(O)0-2—; and Y is —(CH2)1-2—, —C(?O)—, —C(?NOR13)— or —SO0-2—; or M1 is N; M2 is N or CH; X is a bond, alkylene, alkenylene, —C(O)—, —NHC(O)—, —OC(O)— or —S(O)1-2—; Y is —(CH2)1-2—, —C(?O)— or —SO0-2—; and when M2 is CH, Y is also Y is —O— or —C(?NOR13)—; Z is a bond or optionally substituted alkylene or alkenylene; U and W are CH, or one is CH and one is N; R1 is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl; R2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; and compositions and methods of treating obesity, metabolic syndrome and a cognition deficit disorder, alone or in combinatType: GrantFiled: December 19, 2006Date of Patent: February 1, 2011Assignee: Schering CorporationInventors: Daniel M. Solomon, Robert G. Aslanian, Michael Y. Berlin, Manuel de Lera Ruiz, Kevin D. McCormick, Mwangi W. Mutahi, Wing C. Tom
-
Patent number: 7846946Abstract: Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is —C(?O)—, —C(?S)—, —(CH2)q—, —C(?NOR7)— or —SO1-2—; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, or alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, all optionally substituted, or a group of the formula: where ring A is a heteroaryl ring; R2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R3 is H, —C(O)NH2, or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with otheType: GrantFiled: July 22, 2009Date of Patent: December 7, 2010Assignee: Schering Plough CorporationInventors: Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Chao, Manuel de Lera Ruiz, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom, Henry A. Vaccaro, Junying Zheng, Xiaohong Zhu
-
Patent number: 7638531Abstract: Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: M is CH or N; U and W are each CH, or one of U and W is CH and the other is N; X is a bond, alkylene, —C(O)—, —C(N—OR5)—, —C(N—OR5)—CH(R6)—, —CH(R6)—C(N—OR5)—, —O—, —OCH2—, —CH2O— or —S(O)0-2—; Y is —O—, —(CH2)2—, —C(?O)—, —C(?NOR7)— or —SO0-2—; Z is a bond, optionally substituted alkylene or alkylene interrupted by a heteroatom or heterocyclic group; R1 is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, or benzimidazolyl or a derivative thereof; R2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods for treating an allergy-induced airway response, congestion, diabetes, obesity, an obesity-related disorder, metabolic syndrome and a cognition deficit disorder using said compounds, alone or in combinatioType: GrantFiled: December 19, 2006Date of Patent: December 29, 2009Assignee: Schering CorporationInventors: Mwangi W. Mutahi, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Manuel de Lera Ruiz, Kevin D. McCormick, Daniel M. Solomon, Henry A. Vaccaro, Junying Zheng, Purakkattle Biju, Younong Yu, Wei Zhou, Xiaohong Zhu
-
Patent number: 7635705Abstract: Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is —C(?O)—, —C(?S)—, —(CH2)q—, —C(?NOR7)— or —SO1-2—; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, or alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, all optionally substituted, or a group of the formula: where ring A is a heteroaryl ring; R2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R3 is H, —C(O)NH2, or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with othType: GrantFiled: June 19, 2006Date of Patent: December 22, 2009Assignee: Schering CorporationInventors: Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Chao, Manuel de Lera Ruiz, Pietro Mangiaracina, Kevin D. McCormick, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom, Henry A. Vaccaro, Junying Zheng, Xiaohong Zhu, Mwangi W. Mutahi
-
HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS
Publication number: 20090286830Abstract: Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is —C(?O)—, —C(?S)—, —(CH2)q—, —C(?NOR7)— or —SO1-2—; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, or alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, all optionally substituted, or a group of the formula: where ring A is a heteroaryl ring; R2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R3 is H, —C(O)NH2, or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with otheType: ApplicationFiled: July 22, 2009Publication date: November 19, 2009Inventors: Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Chao, Manuel de Lera Ruiz, Pietro Mangiaracina, Kevin D. McCormick, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom, Henry A. Vaccaro, Junying Zheng, Xiaohong Zhu, Mwangi W. Mutahi -
Patent number: 7238688Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.Type: GrantFiled: October 27, 2004Date of Patent: July 3, 2007Assignee: Schering CorporationInventors: Stuart B. Rosenblum, Qingbei Zeng, Mwangi Wa Mutahi, Robert G. Aslanian, Pauline C. Ting, Neng-Yang Shih, Daniel M. Solomon, Jianhua Cao, Henry A. Vaccaro, Kevin D. McCormick, John J. Baldwin, Ge Li
-
Patent number: 7220735Abstract: Disclosed are novel compounds of the formula wherein R1 is benzimidazolone derivative, M1 and M2 are optionally substituted carbon or nitrogen, R2 includes optionally substituted aryl or heteroaryl, and the remaining variables are as defined in the specification, and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an H1 receptor antagonist.Type: GrantFiled: April 16, 2003Date of Patent: May 22, 2007Assignee: Schering CorporationInventors: Pauline C. Ting, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Cao, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom, Qingbei Zeng
-
Patent number: 7105505Abstract: Disclosed are novel compounds of the formula wherein R1 is optionally substituted benzimidazolyl or a derivative thereof; R2 is optionally substituted aryl or heteroaryl; M1 and M2 are C(R3) or N; and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an H1 receptor antagonist.Type: GrantFiled: April 16, 2003Date of Patent: September 12, 2006Assignee: Schering CorporationInventors: Qingbei Zeng, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Cao, Joseph A. Kozlowski, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom
-
Patent number: 6849621Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H. receptor antagonist.Type: GrantFiled: March 11, 2002Date of Patent: February 1, 2005Assignees: Schering Corporation, Pharmacopeia Drug Discovery, Inc.Inventors: Stuart B. Rosenblum, Qingbei Zeng, Mwangi Wa Mutahi, Robert G. Aslanian, Pauline C. Ting, Neng-Yang Shih, Daniel M. Solomon, Jianhua Cao, Henry A. Vaccaro, Kevin D. McCormick, John J. Baldwin, Ge Li
-
Patent number: 6762186Abstract: The present invention discloses novel substituted imidazole compounds which have H3 receptor antagonist or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, nasal congestion, inflammatory and CNS-related diseases and others.Type: GrantFiled: September 18, 2001Date of Patent: July 13, 2004Assignee: Schering CorporationInventors: Neng-Yang Shih, Robert G. Aslanian, Daniel M. Solomon, Stuart B. Rosenblum, Mwangi Wa Mutahi, Tom G. Wing, Kevin D. McCormick, John J. Piwinski, Ronald Wolin
-
Publication number: 20040097483Abstract: Disclosed are novel compounds of the formula 1Type: ApplicationFiled: April 16, 2003Publication date: May 20, 2004Inventors: Qingbei Zeng, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Cao, Joseph A. Kozlowski, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom
-
Publication number: 20040048843Abstract: Disclosed are novel compounds of the formula 1Type: ApplicationFiled: April 16, 2003Publication date: March 11, 2004Applicant: Schering CorporationInventors: Pauline C. Ting, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Jianhua Cao, Pietro Mangiaracina, Kevin D. McCormick, Mwangi W. Mutahi, Stuart B. Rosenblum, Neng-Yang Shih, Daniel M. Solomon, Wing C. Tom, Qingbei Zeng
-
Publication number: 20030109564Abstract: Disclosed are novel compounds of the formula 1Type: ApplicationFiled: March 11, 2002Publication date: June 12, 2003Applicant: Schering CorporationInventors: Stuart B. Rosenblum, Qingbei Zeng, Mwangi Wa Mutahi, Robert G. Aslanian, Pauline C. Ting, Neng-Yang Shih, Daniel M. Solomon, Jianhua Cao, Henry A. Vaccaro, Kevin D. McCormick, John J. Baldwin, Ge Li
-
Patent number: 6506756Abstract: The present invention discloses novel substituted imidazole compounds which have dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, inflammatory and CNS-related diseases and others.Type: GrantFiled: September 18, 2001Date of Patent: January 14, 2003Assignee: Schering CorporationInventors: Neng-Yang Shih, Daniel M. Solomon, John J. Piwinski, Andrew T. Lupo, Jr., Michael J. Green
-
Publication number: 20020086859Abstract: The present invention discloses novel substituted imidazole compounds which have dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, inflammatory and CNS-related diseases and others.Type: ApplicationFiled: September 18, 2001Publication date: July 4, 2002Inventors: Neng-Yang Shih, Daniel M. Solomon, John J. Piwinski, Andrew T. Lupo, Michael J. Green
-
Publication number: 20020082278Abstract: The present invention discloses novel substituted imidazole compounds which have H3 receptor antagonist or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, nasal congestion, inflammatory and CNS-related diseases and others.Type: ApplicationFiled: September 18, 2001Publication date: June 27, 2002Inventors: Neng-Yang Shih, Robert G. Aslanian, Daniel M. Solomon, Stuart B. Rosenblum, Mwangi Wa Mutahi, Wing C. Tom, Kevin D. Mc Cormick, John J. Piwinski, Ronald Wolin
-
Patent number: 6211182Abstract: This invention discloses novel imidazoles substituted with a six or seven membered heterocyclic ring which contains two nitrogen atoms as part of the heterocyclic ring structure. These compounds have excellent histamine-H3 receptor antagonist activity. Also disclosed are methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma)—i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypomotility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimer's Disease, schizophrenia, and migraine).Type: GrantFiled: March 8, 1999Date of Patent: April 3, 2001Assignee: Schering CorporationInventors: Wayne Vaccaro, John J. Piwinski, Wing C. Tom, Daniel M. Solomon, Robert G. Aslanian
-
Patent number: 6100279Abstract: Disclosed are compounds of Formula I ##STR1## or pharmaceutically acceptable salts or solvates thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of Formula I. Further disclosed is a method of treating allergy (for example asthma), inflammation, hypotension, raised intraocular pressure (such as glaucoma)--i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypo motility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimer's, schizophrenia, obesity and migraine) comprising administering an effective amount of a compound of Formula I to a patient in need of such treatment.Type: GrantFiled: November 5, 1998Date of Patent: August 8, 2000Assignee: Schering CorporationInventors: Wayne D. Vaccaro, Ronald L. Wolin, Daniel M. Solomon, Robert G. Aslanian, John J. Piwinski, Stuart B. Rosenblum